{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:43:10Z","timestamp":1778931790085,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"46","license":[{"start":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T00:00:00Z","timestamp":1425254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T00:00:00Z","timestamp":1425254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,11,12]]},"DOI":"10.1038\/onc.2015.20","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T11:00:08Z","timestamp":1425294008000},"page":"5718-5728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma"],"prefix":"10.1038","volume":"34","author":[{"given":"Y","family":"Gui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Yeganeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-C","family":"Donates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W-S","family":"Tobelaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Chababi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mayhue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Saucier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ilangumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,2]]},"reference":[{"key":"BFonc201520_CR1","first-page":"29","volume":"28","author":"H Yoshikawa","year":"2001","unstructured":"Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE et al. SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth- suppression activity. Nat Genet 2001; 28: 29\u201335.","journal-title":"Nat Genet"},{"key":"BFonc201520_CR2","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20031675","volume":"199","author":"T Yoshida","year":"2004","unstructured":"Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004; 199: 1701\u20131707.","journal-title":"J Exp Med"},{"key":"BFonc201520_CR3","first-page":"e24053","volume":"2","author":"K Inagaki-Ohara","year":"2013","unstructured":"Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A . SOCS, inflammation, and cancer. JAKSTAT 2013; 2: e24053.","journal-title":"JAKSTAT"},{"key":"BFonc201520_CR4","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s00018-014-1619-y","volume":"71","author":"JU Kazi","year":"2014","unstructured":"Kazi JU, Kabir NN, Flores-Morales A, Ronnstrand L . SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci 2014; 71: 3297\u20133310.","journal-title":"Cell Mol Life Sci"},{"key":"BFonc201520_CR5","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jhep.2011.03.027","volume":"55","author":"Y Gui","year":"2011","unstructured":"Gui Y, Yeganeh M, Ramanathan S, Leblanc C, Pomerleau V, Ferbeyre G et al. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol 2011; 55: 1300\u20131308.","journal-title":"J Hepatol"},{"key":"BFonc201520_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrd2530","volume":"7","author":"PM Comoglio","year":"2008","unstructured":"Comoglio PM, Giordano S, Trusolino L . Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504\u2013516.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc201520_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino L, Bertotti A, Comoglio PM . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834\u2013848.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc201520_CR8","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1038\/sj.onc.1210522","volume":"26","author":"HH Mak","year":"2007","unstructured":"Mak HH, Peschard P, Lin T, Naujokas MA, Zuo D, Park M . Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene 2007; 26: 7213\u20137221.","journal-title":"Oncogene"},{"key":"BFonc201520_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1083\/jcb.200806076","volume":"182","author":"S Kermorgant","year":"2008","unstructured":"Kermorgant S, Parker PJ . Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008; 182: 855\u2013863.","journal-title":"J Cell Biol"},{"key":"BFonc201520_CR10","doi-asserted-by":"publisher","first-page":"24956","DOI":"10.1074\/jbc.M110.127985","volume":"285","author":"JV Abella","year":"2010","unstructured":"Abella JV, Parachoniak CA, Sangwan V, Park M . Dorsal ruffle microdomains potentiate Met receptor tyrosine kinase signaling and down-regulation. J Biol Chem 2010; 285: 24956\u201324967.","journal-title":"J Biol Chem"},{"key":"BFonc201520_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1128\/MCB.17.2.799","volume":"17","author":"M Jeffers","year":"1997","unstructured":"Jeffers M, Taylor GA, Weidner KM, Omura S, Vande Woude GF . Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol 1997; 17: 799\u2013808.","journal-title":"Mol Cell Biol"},{"key":"BFonc201520_CR12","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/sj.onc.1204475","volume":"20","author":"DE Hammond","year":"2001","unstructured":"Hammond DE, Urbe S, Vande Woude GF, Clague MJ . Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001; 20: 2761\u20132770.","journal-title":"Oncogene"},{"key":"BFonc201520_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nri818","volume":"2","author":"WS Alexander","year":"2002","unstructured":"Alexander WS . Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002; 2: 1\u20137.","journal-title":"Nat Rev Immunol"},{"key":"BFonc201520_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1189\/jlb.1003507","volume":"75","author":"JA Johnston","year":"2004","unstructured":"Johnston JA . Are SOCS suppressors, regulators, and degraders? J Leukoc Biol 2004; 75: 743\u2013748.","journal-title":"J Leukoc Biol"},{"key":"BFonc201520_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fonc.2012.00010","volume":"2","author":"F Okumura","year":"2012","unstructured":"Okumura F, Matsuzaki M, Nakatsukasa K, Kamura T . The role of elongin BC-containing ubiquitin ligases. Front Oncol 2012; 2: 10.","journal-title":"Front Oncol"},{"key":"BFonc201520_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2007.08.020","volume":"48","author":"E Seki","year":"2008","unstructured":"Seki E, Kondo Y, Iimuro Y, Naka T, Son G, Kishimoto T et al. Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings. J Hepatol 2008; 48: 237\u2013245.","journal-title":"J Hepatol"},{"key":"BFonc201520_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.smim.2004.08.015","volume":"16","author":"S Ilangumaran","year":"2004","unstructured":"Ilangumaran S, Ramanathan S, Rottapel R . Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol 2004; 16: 351\u2013365.","journal-title":"Semin Immunol"},{"key":"BFonc201520_CR18","first-page":"359","volume":"5","author":"H Zhu","year":"1994","unstructured":"Zhu H, Naujokas MA, Park M . Receptor chimeras indicate that the met tyrosine kinase mediates the motility and morphogenic responses of hepatocyte growth\/scatter factor. Cell Growth Differ 1994; 5: 359\u2013366.","journal-title":"Cell Growth Differ"},{"key":"BFonc201520_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/emboj\/18.4.904","volume":"18","author":"P De Sepulveda","year":"1999","unstructured":"De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R . Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J 1999; 18: 904\u2013915.","journal-title":"EMBO J"},{"key":"BFonc201520_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","volume":"8","author":"P Peschard","year":"2001","unstructured":"Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001; 8: 995\u20131004.","journal-title":"Mol Cell"},{"key":"BFonc201520_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1074\/jbc.M110.169821","volume":"286","author":"AR Grassian","year":"2011","unstructured":"Grassian AR, Schafer ZT, Brugge JS . ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cells. J Biol Chem 2011; 286: 79\u201390.","journal-title":"J Biol Chem"},{"key":"BFonc201520_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1747-1028-2-11","volume":"2","author":"T Woelk","year":"2007","unstructured":"Woelk T, Sigismund S, Penengo L, Polo S . The ubiquitination code: a signalling problem. Cell Div 2007; 2: 11.","journal-title":"Cell Div"},{"key":"BFonc201520_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1042\/BJ20050892","volume":"391","author":"CB Thien","year":"2005","unstructured":"Thien CB, Langdon WY . c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem J 2005; 391: 153\u2013166.","journal-title":"Biochem J"},{"key":"BFonc201520_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/ncb983","volume":"5","author":"K Haglund","year":"2003","unstructured":"Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I . Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 2003; 5: 461\u2013466.","journal-title":"Nat Cell Biol"},{"key":"BFonc201520_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ng1007","volume":"32","author":"G Zardo","year":"2002","unstructured":"Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet 2002; 32: 453\u2013458.","journal-title":"Nat Genet"},{"key":"BFonc201520_CR26","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-09-4250","volume":"70","author":"S Jiang","year":"2010","unstructured":"Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70: 3119\u20133127.","journal-title":"Cancer Res"},{"key":"BFonc201520_CR27","doi-asserted-by":"publisher","first-page":"E1695","DOI":"10.1073\/pnas.1201516109","volume":"109","author":"IA Babar","year":"2012","unstructured":"Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA 2012; 109: E1695\u2013E1704.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201520_CR28","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.18632\/oncotarget.696","volume":"3","author":"N Kobayashi","year":"2012","unstructured":"Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012; 3: 1455\u20131471.","journal-title":"Oncotarget"},{"key":"BFonc201520_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500\u2013504.","journal-title":"Nature"},{"key":"BFonc201520_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505\u2013509.","journal-title":"Nature"},{"key":"BFonc201520_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3277","volume":"12","author":"JB Casaletto","year":"2012","unstructured":"Casaletto JB, McClatchey AI . Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 2012; 12: 387\u2013400.","journal-title":"Nat Rev Cancer"},{"key":"BFonc201520_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1470-2045(09)70137-8","volume":"10","author":"MV Karamouzis","year":"2009","unstructured":"Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG . Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10: 709\u2013717.","journal-title":"Lancet Oncol"},{"key":"BFonc201520_CR33","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-10-0163","volume":"70","author":"AM Xu","year":"2010","unstructured":"Xu AM, Huang PH . Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010; 70: 3857\u20133860.","journal-title":"Cancer Res"},{"key":"BFonc201520_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G . Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89\u2013103.","journal-title":"Nat Rev Cancer"},{"key":"BFonc201520_CR35","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/sj.onc.1210201","volume":"26","author":"P Peschard","year":"2007","unstructured":"Peschard P, Park M . From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007; 26: 1276\u20131285.","journal-title":"Oncogene"},{"key":"BFonc201520_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1083\/jcb.200106056","volume":"156","author":"KE Longva","year":"2002","unstructured":"Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH . Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002; 156: 843\u2013854.","journal-title":"J Cell Biol"},{"key":"BFonc201520_CR37","doi-asserted-by":"publisher","first-page":"e23936","DOI":"10.1371\/journal.pone.0023936","volume":"6","author":"L Zhou","year":"2011","unstructured":"Zhou L, Yang H . The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One 2011; 6: e23936.","journal-title":"PLoS One"},{"key":"BFonc201520_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1172\/JCI31537","volume":"117","author":"WW Lin","year":"2007","unstructured":"Lin WW, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175\u20131183.","journal-title":"J Clin Invest"},{"key":"BFonc201520_CR39","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/hep.20969","volume":"43","author":"N Fausto","year":"2006","unstructured":"Fausto N, Campbell JS, Riehle KJ . Liver regeneration. Hepatology 2006; 43: S45\u2013S53.","journal-title":"Hepatology"},{"key":"BFonc201520_CR40","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-12-2791","volume":"19","author":"L Goyal","year":"2013","unstructured":"Goyal L, Muzumdar MD, Zhu AX . Targeting the HGF\/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 2013; 19: 2310\u20132318.","journal-title":"Clin Cancer Res"},{"key":"BFonc201520_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1146\/annurev.pharmtox.45.120403.095832","volume":"45","author":"M Esteller","year":"2005","unstructured":"Esteller M . Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629\u2013656.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFonc201520_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.bjc.6601039","volume":"89","author":"N Fukushima","year":"2003","unstructured":"Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, Goggins M . Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 2003; 89: 338\u2013343.","journal-title":"Br J Cancer"},{"key":"BFonc201520_CR43","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/0008-5472.CAN-12-1880","volume":"73","author":"R Shakya","year":"2013","unstructured":"Shakya R, Gonda T, Quante M, Salas M, Kim S, Brooks J et al. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. Cancer Res 2013; 73: 885\u2013896.","journal-title":"Cancer Res"},{"key":"BFonc201520_CR44","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/emboj\/18.5.1309","volume":"18","author":"H Yasukawa","year":"1999","unstructured":"Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999; 18: 1309\u20131320.","journal-title":"EMBO J"},{"key":"BFonc201520_CR45","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.4049\/jimmunol.169.9.5010","volume":"169","author":"S Ilangumaran","year":"2002","unstructured":"Ilangumaran S, Finan D, La Rose J, Raine J, Silverstein A, De Sepulveda P et al. A positive regulatory role for SOCS1 in interferon gamma-induced MHC class II expression in fibroblasts. J Immunol 2002; 169: 5010\u20135020.","journal-title":"J Immunol"},{"key":"BFonc201520_CR46","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1523\/JNEUROSCI.4474-04.2005","volume":"25","author":"KL Lim","year":"2005","unstructured":"Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005; 25: 2002\u20132009.","journal-title":"J Neurosci"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc201520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201520","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:29:49Z","timestamp":1647894589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc201520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,2]]},"references-count":46,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2015,11,12]]}},"alternative-id":["BFonc201520"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.20","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,2]]},"assertion":[{"value":"25 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YG is a recipient of a graduate student fellowship from the Canadian Liver Foundation. MY was a recipient of FRQNT doctoral fellowship. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}